文献类型：期刊文献

英文题名：Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy

作者：Wu, Yunzhou[1];He, Jinjiao[2];Geng, Jingshu[3];An, Ying[1];Ye, Xianlong[4];Yan, Shijun[1];Yu, Qingzhong[5];Yin, Jiechao[1];Zhang, Zhenyu[6];Li, Deshan[1]

第一作者：Wu, Yunzhou

通讯作者：Li, DS[1];Zhang, ZY[2]

机构：[1]Northeast Agr Univ, Coll Life Sci, Mucai St 59, Harbin, Peoples R China;[2]Xinxiang Univ, Coll Life Sci & Technol, Jinsui Ave, Xinxiang, Peoples R China;[3]Harbin Med Univ, Affiliated Tumor Hosp, Pathol Dept, Yiyuan St 37, Harbin, Peoples R China;[4]Henan Normal Univ, Sch Life Sci, 46 Jianshe Rd E, Xinxiang, Peoples R China;[5]ARS, Southeast Poultry Res Lab, USDA, 934 Coll Stn Rd, Athens, GA 30605 USA;[6]Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin 150001, Peoples R China

第一机构：Northeast Agr Univ, Coll Life Sci, Mucai St 59, Harbin, Peoples R China

通讯机构：[1]corresponding author), Northeast Agr Univ, Coll Life Sci, Mucai St 59, Harbin, Peoples R China;[2]corresponding author), Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin 150001, Peoples R China.

年份：2017

卷号：802

起止页码：85-92

外文期刊名：EUROPEAN JOURNAL OF PHARMACOLOGY

收录：;Scopus(收录号：2-s2.0-85014074717);WOS:【SCI-EXPANDED(收录号:WOS:000400222900011)】；

基金：This work is supported by National Natural Science Foundation of China (Grant no. 31502050), Heilongjiang Funds for Young Scientists (Grant no. QC2012C099), Department for Heilongjiang Education Fund (Grant no. 12541046), Department for Harbin Science and Technology Funds for Young Scientists (Grant no. 2014RFQXJ118) and Young Talents Project of Northeast Agricultural University (Grant no. 16QC29).

语种：英文

外文关键词：Newcastle disease virus; Oncolysis; Hepatoma; Hepatocellular carcinoma; TRAIL

摘要：Newcastle disease-virus (NDV) have shown oncolytic therapeutic efficacy in preclinical studies and are currently proved for clinical trials. We have previously reported, for the first time, NDV Anhinga strain has an efficient cancer therapeutic efficacy in hepatoma. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) functions as a cytokine to selectively kill various cancer cells without toxicity to most normal cells. Numerous studies have demonstrated the potential use of recombinant soluble TRAIL as a cancer therapeutic agent. In this study, we have showed administration of a recombinant NDV Anhinga strain expressing soluble TRAIL (NDV/Anh-TRAIL) results in an efficient suppression of hepatocellular carcinoma without significant toxicity. The results show that recombinant NDV Anhinga strain expressing soluble TRAIL is a promising candidate for hepatoma therapy.